Adamantane barely behaves like a hydrocarbon. The NIST Chemistry WebBook lists an enthalpy of sublimation of 59 ± 4 kJ mol-1, averaged over eighteen separate determinations, and two independently reported melting points — 552 K and 542.15 K — for a molecule of only ten carbons. In practice it is handled as a subliming solid rather than a distillable liquid.
The formula is C10H16, the CAS number 281-23-2, the molecular weight 136.234, and the systematic name tricyclo[3.3.1.13,7]decane. That name is the whole molecule. Three fused six-membered rings share four bridgehead carbons; every ring is locked in a chair; the carbon skeleton is a single repeating unit cut directly out of the diamond lattice. Nothing in it can rotate, pucker or invert.
Adamantane chemistry starts with a cage that cannot flex
Rigidity is the property that makes the rest of adamantane chemistry follow. Conformational freedom costs entropy when a ligand binds a protein, and a cage that has none pays that cost in advance. It also removes the soft, oxidisable positions that flexible alkyl chains offer to metabolising enzymes.
The solid state is equally unusual. NIST records a crystalline phase transition at 208.62 K between phases II and I, with an enthalpy of 3.376 kJ mol-1 — the lattice reorganises well below room temperature without the compound ever melting. Above that point the material is the waxy, camphor-smelling solid most chemists have handled.
For a pure hydrocarbon the cage is also compact and greasy in a way that matters later: PubChem gives adamantane a computed XLogP3 of 3.8 at a molecular weight of 136. Few fragments of that size carry that much lipophilicity into a molecule.
From petroleum trace to bench chemical
Adamantane was not made first. It was found. It was isolated from petroleum in 1933, where a 2021 review in Organic & Biomolecular Chemistry puts its natural abundance at roughly 0.0004 %. At that concentration it was a museum piece.
The first synthesis came eight years later. Vlado Prelog and Rativoj Seiwerth published Über die Synthese des Adamantans in Berichte der deutschen chemischen Gesellschaft in 1941, building the cage through enolate alkylation and Wolff–Kishner reductions. The same review records the yield over the final steps as 1.5 %. The structure was proved, and the compound remained effectively unobtainable.
The break came in 1957 and it came by accident. Paul von Ragué Schleyer was trying to convert endo-tetrahydrodicyclopentadiene into its exo isomer over a Lewis acid. What he got instead was adamantane. His report, A Simple Preparation of Adamantane, occupies a single page of the Journal of the American Chemical Society — volume 79, page 3292. Refluxing the hydrogenated dicyclopentadiene with aluminium halide drives a cascade of carbocation rearrangements that funnels the strained tricyclic skeleton downhill into the most thermodynamically stable C10H16 arrangement there is. The review cited above gives the optimised yield range as 20–40 %.
Two steps from a cheap petrochemical, at twenty-fold better yield than the classical route. The price collapsed, and the medicinal chemistry that followed only became possible at that moment.
Where the cage actually reacts
Adamantane has exactly two kinds of C–H bond. Four tertiary bridgehead hydrogens sit at C1, C3, C5 and C7; six secondary methylene hydrogens occupy the remaining positions. Both are strong — the Organic & Biomolecular Chemistry review quotes bond dissociation energies in the 96–99 kcal mol-1 range for the two environments, unusually high for a saturated hydrocarbon.
Reactivity is therefore a question of access rather than of weakness. Most direct functionalisation methods, radical and ionic alike, strongly prefer the tertiary bridgehead positions. The same review attributes this to sterics: an incoming reagent approaching a secondary C–H runs into significant 1,3-diaxial interactions, while the bridgehead is comparatively exposed.
The practical consequence is that 1-substituted adamantanes are easy and 2-substituted adamantanes are not. Amantadine, the antiviral, is adamantan-1-amine — the easy position. That asymmetry shapes which adamantyl building blocks appear in catalogues and which have to be built the long way round.
The adamantyl group as a lipophilic add-on
Medicinal chemists use adamantane the way a formulator uses a solvent: as a property, not as a pharmacophore in its own right. Bolting the cage onto an existing scaffold adds lipophilicity, adds steric bulk, adds rigidity, and blocks metabolic soft spots, usually without introducing a new hydrogen bond donor or acceptor.
The review lists several approved drugs built this way: memantine, approved by the FDA in 2003 for Alzheimer’s disease; adapalene, an anti-acne retinoid; saxagliptin, a DPP-4 inhibitor for diabetes; and amantadine, whose anti-influenza A activity was later undermined by widespread viral resistance. Four different target classes, one shared fragment.
The lipophilicity arithmetic is visible in PubChem’s computed descriptors:
| Compound | Formula | MW | XLogP3 |
|---|---|---|---|
| Adamantane | C10H16 | 136.23 | 3.8 |
| Bromantane | C16H20BrN | 306.24 | 5.0 |
Bromantane and the larger diamondoids
Bromantane is, structurally, an adamantane derivative with a single aryl amine substituent. PubChem records it as CID 4660557, formula C16H20BrN, molecular weight 306.24, IUPAC name N-(4-bromophenyl)adamantan-2-amine.
The locant is the interesting part. It is adamantan-2-amine, not adamantan-1-amine — the nitrogen sits on a secondary methylene carbon, the disfavoured position described above, rather than on a bridgehead. That distinguishes it structurally from amantadine, rimantadine and memantine, which are all bridgehead-substituted, and it means the compound cannot be assembled by the simple bridgehead functionalisation chemistry that makes those molecules cheap. Laboratories working on such compounds characterise them against an analytical reference standard of known identity and purity, because regiochemistry of this kind is exactly what a certificate of analysis has to pin down.
Adamantane is also not the end of the series. In 2003 Dahl, Liu and Carlson reported in Science the isolation of higher diamondoids from petroleum — molecules containing four to eleven fused diamond cages, obtained by vacuum-distilling fractions boiling above 345 °C and pyrolysing them at 400–450 °C to destroy everything that was not a diamondoid. They obtained single-crystal X-ray structures for representatives of three families. Adamantane, in that light, is simply the one-cage member of a family of hydrocarbons that crude oil has been quietly manufacturing underground.
Frequently asked questions
What is adamantane?
Adamantane is a saturated tricyclic hydrocarbon, C10H16, CAS 281-23-2, systematically named tricyclo[3.3.1.13,7]decane. Its carbon skeleton is a single repeating unit of the diamond lattice, which makes it completely rigid. NIST lists melting points of 552 K and 542.15 K and an enthalpy of sublimation of 59 ± 4 kJ mol-1.
Why is adamantane used in drug molecules?
The adamantyl cage is added to existing scaffolds to raise lipophilicity, add steric bulk and rigidity, and block metabolically vulnerable positions. PubChem gives the bare cage an XLogP3 of 3.8 at a molecular weight of 136. Approved drugs carrying the fragment include memantine, adapalene, saxagliptin and amantadine.
How is adamantane made?
Industrially, by the route Schleyer reported in 1957: dicyclopentadiene is hydrogenated to tetrahydrodicyclopentadiene, then rearranged over a Lewis acid such as aluminium chloride or aluminium bromide. Carbocation rearrangements funnel the skeleton into the most stable C10H16 isomer. Reported yields for the optimised process are 20–40 %.
What is the difference between adamantan-1-yl and adamantan-2-yl substitution?
Position 1 is a tertiary bridgehead carbon; position 2 is a secondary methylene carbon. Direct C–H functionalisation strongly favours the bridgehead, because approach to a secondary C–H suffers 1,3-diaxial steric interactions. Amantadine and memantine are bridgehead-substituted; bromantane, an N-(4-bromophenyl)adamantan-2-amine, is not.
References
- NIST Chemistry WebBook, Adamantane (CAS 281-23-2) — identifiers and phase change data
- PubChem CID 9238, Adamantane — computed properties
- PubChem CID 4660557, Bromantane — computed properties
- Prelog V, Seiwerth R. Über die Synthese des Adamantans. Ber. dtsch. chem. Ges. 1941;74:1644–1648
- Schleyer P von R. A Simple Preparation of Adamantane. J. Am. Chem. Soc. 1957;79(12):3292
- Weigel WK III, Dang HT, Feceu A, Martin DBC. Direct radical functionalization methods to access substituted adamantanes and diamondoids. Org. Biomol. Chem. 2022;20(1):10–36
- Dahl JE, Liu SG, Carlson RMK. Isolation and structure of higher diamondoids, nanometer-sized diamond molecules. Science 2003;299(5603):96–99
Research use only. Nonsensia Lab supplies analytical reference standards for laboratory and research applications. This article is published for scientific and educational purposes. It is not medical advice, it does not describe any use in humans, and nothing in it should be read as a recommendation to administer any substance to a person or animal.
Filed under: Chemistry & Discovery
This article is part of our guide to Where Research Compounds Come From: Discovery, Synthesis and Structure.
The compound discussed in this article is available as an analytical reference standard: Bromantane ≥99.75% HPLC – Analytical Reference Standard | CAS 87913-26-6.